Home | Medical Need | R&D Programmes | Company | Collaborations | News |
| Multi-resistant bacteria at large In the U.S. alone, 99 000 patients per year die from hospital-acquired infections, most often caused by multi-drug resistant bacteria. Fortunately, new effective antibiotics have been developed against multi-resistant Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VRE), but about half of the hospital-acquired infections are caused by Gram-negatives. |
| Northern Antibiotics fights against multi-resistant Gram-negatives Northern Antibiotics has developed two series of novel compounds which are highly effective against difficult-to-treat Gram-negative bacteria including multi-resistant Escherichia coli, Klebsiella pneumoniae, other species of Enterobacteriaceae, and Acinetobacter baumannii. |
| We come from Finland Northern Antibiotics is a venture-capital-backed R&D company founded in 2003. Professor Martti Vaara, M.D., Ph.D., co-founder of the company, is a broadly acknowledged expert in the outer membrane of Gram-negative bacteria. |
| Collaborations on four continents Rather than investing heavily in its own infrastructure, Northern Antibiotics outsources most of the laboratory research to academic groups and contract research organizations, each world-renowned in its own field of expertise. |
Mailing Address: P.O.Box 30, FIN-00721, Helsinki, Finland
Visiting Address: Eskolantie 1, FIN-00720, Helsinki, Finland
Phone: + 358-50-355 0822
Fax: +358-9-6842 0130
E-mail: info@northernantibiotics.com
